Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Assessing the Feasibility and Toxicity of Degarelix in Achieving Prostate Downsizing Prior to Treatment With Permanent Seed Prostate Brachytherapy

NCT01446991 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT01446991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01446991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Assessing the Feasibility and Toxicity of Degarelix in Achieving Prostate Downsizing Prior to Treatment With Permanent Seed Prostate Brachytherapy
Lead sponsor
British Columbia Cancer Agency
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2012
Completion date
December 31, 2017
Enrollment
50 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer